Hospital Variations and Temporal Trends in Procalcitonin Use for Patients With Bronchiolitis.

Background and objective: The financial burden of bronchiolitis-related hospitalizations in the United States surpasses $700 million annually. Procalcitonin (PCT) has garnered recent interest in pediatrics and has demonstrated the potential to decrease antibiotic usage in other illnesses. This study assessed PCT utilization trends in bronchiolitis, hypothesizing an annual increase in PCT testing.

Methods: We conducted a multicenter, retrospective cross-sectional study utilizing the Pediatric Health Information Systems database. Infants aged 2 to 23 months presenting with bronchiolitis from January 1, 2016, to December 31, 2022, were included. Encounters with and without PCT testing were compared using χ2 testing and Wilcoxon rank-sum testing as appropriate. Temporal trends in PCT testing and correlations with hospital-level proportions of PCT use, antibiotic administration, and admission proportion were assessed using Spearman's ρ.

Results: There were 366 643 bronchiolitis encounters among 307 949 distinct patients across 38 hospitals during the study period. Of those, 1.5% (5517 of 366 643) had PCT testing performed. PCT usage increased more than 14-fold between 2016 and 2022 (0.2% in 2016 vs 2.8% in 2022, ρ > 0.99, P < .001). PCT use ranged from 0.01% to 8.29% across hospitals. The hospital-level proportion of PCT testing was not associated with admissions (ρ = 0.13, P = .42) or antibiotic use (ρ = 0.31, P = .06).

Conclusions: PCT testing in patients with bronchiolitis increased 14-fold between 2016 and 2022 and was not associated with decreased antimicrobial prescriptions. Further studies are needed to determine the diagnostic yield of PCT in bronchiolitis.